American pharmaceutical company Moderna submitted an application to the Ministry of Health, Labor and Welfare on the 10th seeking approval for a new coronavirus vaccine for the Omicron strain.

It is the second company to apply for approval of a vaccine for the Omicron strain, following Pfizer, which applied on the 8th.

According to Moderna's announcement, we applied for approval to the Ministry of Health, Labor and Welfare for the Omicron strain ``BA. This type of vaccine is intended for ages 18 and over.



In a clinical trial conducted in the United States, when the vaccine for the Omicron strain was administered as the fourth vaccination, the neutralizing antibody value against "BA.1" was 1.75 times higher than when the conventional vaccine was administered. , the number of neutralizing antibodies against BA.5, which is currently spreading, increased 1.69 times.



Pfizer also applied for approval of a vaccine for the Omicron strain on the 8th, making this the second company.



Moderna is also working on a vaccine for BA.5.